A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

Omid Hamid, Henrik Schmidt, Aviram Nissan, Laura Ridolfi, Steinar Aamdal, Johan Hansson, Michele Guida, David M. Hyams, Henry Gómez, Lars Bastholt, Scott D. Chasalow, David Berman

Research output: Contribution to journalArticle

309 Citations (Scopus)

Abstract

Background: Ipilimumab, a fully human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen-4, has demonstrated an improvement in overall survival in two phase III trials of patients with advanced melanoma. The primary objective of the current trial was to prospectively explore candidate biomarkers from the tumor microenvironment for associations with clinical response to ipilimumab.Methods: In this randomized, double-blind, phase II biomarker study (ClinicalTrials.gov NCT00261365), 82 pretreated or treatment-naïve patients with unresectable stage III/IV melanoma were induced with 3 or 10 mg/kg ipilimumab every 3 weeks for 4 doses; at Week 24, patients could receive maintenance doses every 12 weeks. Efficacy was evaluated per modified World Health Organization response criteria and safety was assessed continuously. Candidate biomarkers were evaluated in tumor biopsies collected pretreatment and 24 to 72 hours after the second ipilimumab dose. Polymorphisms in immune-related genes were also evaluated.Results: Objective response rate, response patterns, and safety were consistent with previous trials of ipilimumab in melanoma. No associations between genetic polymorphisms and clinical activity were observed. Immunohistochemistry and histology on tumor biopsies revealed significant associations between clinical activity and high baseline expression of FoxP3 (p = 0.014) and indoleamine 2,3-dioxygenase (p = 0.012), and between clinical activity and increase in tumor-infiltrating lymphocytes (TILs) between baseline and 3 weeks after start of treatment (p = 0.005). Microarray analysis of mRNA from tumor samples taken pretreatment and post-treatment demonstrated significant increases in expression of several immune-related genes, and decreases in expression of genes implicated in cancer and melanoma.Conclusions: Baseline expression of immune-related tumor biomarkers and a post-treatment increase in TILs may be positively associated with ipilimumab clinical activity. The observed pharmacodynamic changes in gene expression warrant further analysis to determine whether treatment-emergent changes in gene expression may be associated with clinical efficacy. Further studies are required to determine the predictive value of these and other potential biomarkers associated with clinical response to ipilimumab.

Original languageEnglish
Article number204
JournalJournal of Translational Medicine
Volume9
Issue number1
DOIs
Publication statusPublished - Nov 28 2011

Fingerprint

Tumor Microenvironment
Tumor Biomarkers
Melanoma
Association reactions
Tumors
Biomarkers
Tumor-Infiltrating Lymphocytes
Lymphocytes
Biopsy
Genes
Polymorphism
Gene Expression
Gene expression
Neoplasms
Pharmacodynamics
CTLA-4 Antigen
Patient treatment
Indoleamine-Pyrrole 2,3,-Dioxygenase
Therapeutics
Safety

Keywords

  • Cytotoxic t-lymphocyte antigen-4
  • Foxp3
  • Indoleamine 2,3-dioxygenase
  • Ipilimumab
  • Melanoma
  • Tumor biomarker
  • Tumor-infiltrating lymphocytes

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. / Hamid, Omid; Schmidt, Henrik; Nissan, Aviram; Ridolfi, Laura; Aamdal, Steinar; Hansson, Johan; Guida, Michele; Hyams, David M.; Gómez, Henry; Bastholt, Lars; Chasalow, Scott D.; Berman, David.

In: Journal of Translational Medicine, Vol. 9, No. 1, 204, 28.11.2011.

Research output: Contribution to journalArticle

Hamid, Omid ; Schmidt, Henrik ; Nissan, Aviram ; Ridolfi, Laura ; Aamdal, Steinar ; Hansson, Johan ; Guida, Michele ; Hyams, David M. ; Gómez, Henry ; Bastholt, Lars ; Chasalow, Scott D. ; Berman, David. / A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. In: Journal of Translational Medicine. 2011 ; Vol. 9, No. 1.
@article{8d19004f2f3a467f833455688ba16e0e,
title = "A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma",
abstract = "Background: Ipilimumab, a fully human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen-4, has demonstrated an improvement in overall survival in two phase III trials of patients with advanced melanoma. The primary objective of the current trial was to prospectively explore candidate biomarkers from the tumor microenvironment for associations with clinical response to ipilimumab.Methods: In this randomized, double-blind, phase II biomarker study (ClinicalTrials.gov NCT00261365), 82 pretreated or treatment-na{\"i}ve patients with unresectable stage III/IV melanoma were induced with 3 or 10 mg/kg ipilimumab every 3 weeks for 4 doses; at Week 24, patients could receive maintenance doses every 12 weeks. Efficacy was evaluated per modified World Health Organization response criteria and safety was assessed continuously. Candidate biomarkers were evaluated in tumor biopsies collected pretreatment and 24 to 72 hours after the second ipilimumab dose. Polymorphisms in immune-related genes were also evaluated.Results: Objective response rate, response patterns, and safety were consistent with previous trials of ipilimumab in melanoma. No associations between genetic polymorphisms and clinical activity were observed. Immunohistochemistry and histology on tumor biopsies revealed significant associations between clinical activity and high baseline expression of FoxP3 (p = 0.014) and indoleamine 2,3-dioxygenase (p = 0.012), and between clinical activity and increase in tumor-infiltrating lymphocytes (TILs) between baseline and 3 weeks after start of treatment (p = 0.005). Microarray analysis of mRNA from tumor samples taken pretreatment and post-treatment demonstrated significant increases in expression of several immune-related genes, and decreases in expression of genes implicated in cancer and melanoma.Conclusions: Baseline expression of immune-related tumor biomarkers and a post-treatment increase in TILs may be positively associated with ipilimumab clinical activity. The observed pharmacodynamic changes in gene expression warrant further analysis to determine whether treatment-emergent changes in gene expression may be associated with clinical efficacy. Further studies are required to determine the predictive value of these and other potential biomarkers associated with clinical response to ipilimumab.",
keywords = "Cytotoxic t-lymphocyte antigen-4, Foxp3, Indoleamine 2,3-dioxygenase, Ipilimumab, Melanoma, Tumor biomarker, Tumor-infiltrating lymphocytes",
author = "Omid Hamid and Henrik Schmidt and Aviram Nissan and Laura Ridolfi and Steinar Aamdal and Johan Hansson and Michele Guida and Hyams, {David M.} and Henry G{\'o}mez and Lars Bastholt and Chasalow, {Scott D.} and David Berman",
year = "2011",
month = "11",
day = "28",
doi = "10.1186/1479-5876-9-204",
language = "English",
volume = "9",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

AU - Hamid, Omid

AU - Schmidt, Henrik

AU - Nissan, Aviram

AU - Ridolfi, Laura

AU - Aamdal, Steinar

AU - Hansson, Johan

AU - Guida, Michele

AU - Hyams, David M.

AU - Gómez, Henry

AU - Bastholt, Lars

AU - Chasalow, Scott D.

AU - Berman, David

PY - 2011/11/28

Y1 - 2011/11/28

N2 - Background: Ipilimumab, a fully human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen-4, has demonstrated an improvement in overall survival in two phase III trials of patients with advanced melanoma. The primary objective of the current trial was to prospectively explore candidate biomarkers from the tumor microenvironment for associations with clinical response to ipilimumab.Methods: In this randomized, double-blind, phase II biomarker study (ClinicalTrials.gov NCT00261365), 82 pretreated or treatment-naïve patients with unresectable stage III/IV melanoma were induced with 3 or 10 mg/kg ipilimumab every 3 weeks for 4 doses; at Week 24, patients could receive maintenance doses every 12 weeks. Efficacy was evaluated per modified World Health Organization response criteria and safety was assessed continuously. Candidate biomarkers were evaluated in tumor biopsies collected pretreatment and 24 to 72 hours after the second ipilimumab dose. Polymorphisms in immune-related genes were also evaluated.Results: Objective response rate, response patterns, and safety were consistent with previous trials of ipilimumab in melanoma. No associations between genetic polymorphisms and clinical activity were observed. Immunohistochemistry and histology on tumor biopsies revealed significant associations between clinical activity and high baseline expression of FoxP3 (p = 0.014) and indoleamine 2,3-dioxygenase (p = 0.012), and between clinical activity and increase in tumor-infiltrating lymphocytes (TILs) between baseline and 3 weeks after start of treatment (p = 0.005). Microarray analysis of mRNA from tumor samples taken pretreatment and post-treatment demonstrated significant increases in expression of several immune-related genes, and decreases in expression of genes implicated in cancer and melanoma.Conclusions: Baseline expression of immune-related tumor biomarkers and a post-treatment increase in TILs may be positively associated with ipilimumab clinical activity. The observed pharmacodynamic changes in gene expression warrant further analysis to determine whether treatment-emergent changes in gene expression may be associated with clinical efficacy. Further studies are required to determine the predictive value of these and other potential biomarkers associated with clinical response to ipilimumab.

AB - Background: Ipilimumab, a fully human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen-4, has demonstrated an improvement in overall survival in two phase III trials of patients with advanced melanoma. The primary objective of the current trial was to prospectively explore candidate biomarkers from the tumor microenvironment for associations with clinical response to ipilimumab.Methods: In this randomized, double-blind, phase II biomarker study (ClinicalTrials.gov NCT00261365), 82 pretreated or treatment-naïve patients with unresectable stage III/IV melanoma were induced with 3 or 10 mg/kg ipilimumab every 3 weeks for 4 doses; at Week 24, patients could receive maintenance doses every 12 weeks. Efficacy was evaluated per modified World Health Organization response criteria and safety was assessed continuously. Candidate biomarkers were evaluated in tumor biopsies collected pretreatment and 24 to 72 hours after the second ipilimumab dose. Polymorphisms in immune-related genes were also evaluated.Results: Objective response rate, response patterns, and safety were consistent with previous trials of ipilimumab in melanoma. No associations between genetic polymorphisms and clinical activity were observed. Immunohistochemistry and histology on tumor biopsies revealed significant associations between clinical activity and high baseline expression of FoxP3 (p = 0.014) and indoleamine 2,3-dioxygenase (p = 0.012), and between clinical activity and increase in tumor-infiltrating lymphocytes (TILs) between baseline and 3 weeks after start of treatment (p = 0.005). Microarray analysis of mRNA from tumor samples taken pretreatment and post-treatment demonstrated significant increases in expression of several immune-related genes, and decreases in expression of genes implicated in cancer and melanoma.Conclusions: Baseline expression of immune-related tumor biomarkers and a post-treatment increase in TILs may be positively associated with ipilimumab clinical activity. The observed pharmacodynamic changes in gene expression warrant further analysis to determine whether treatment-emergent changes in gene expression may be associated with clinical efficacy. Further studies are required to determine the predictive value of these and other potential biomarkers associated with clinical response to ipilimumab.

KW - Cytotoxic t-lymphocyte antigen-4

KW - Foxp3

KW - Indoleamine 2,3-dioxygenase

KW - Ipilimumab

KW - Melanoma

KW - Tumor biomarker

KW - Tumor-infiltrating lymphocytes

UR - http://www.scopus.com/inward/record.url?scp=82155168544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82155168544&partnerID=8YFLogxK

U2 - 10.1186/1479-5876-9-204

DO - 10.1186/1479-5876-9-204

M3 - Article

C2 - 22123319

AN - SCOPUS:82155168544

VL - 9

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 204

ER -